Avid Radiopharmaceuticals, a molecular imaging company, has begun enrollment in a proof-of-concept phase I clinical trial investigating its development compound, 18F-AV-133, for PET imaging of patients with movement disorders, including Parkinson’s disease, essential tremor, dementias, including dementia with Lewy Bodies and Alzheimer’s disease.
The goal of the trial, to be conducted at the University of Michigan, is to determine whether 18F-AV-133 PET imaging can detect losses in nigrostriatal neurons in the brains of patients, which can indicate these diseases.
The study will involve 30 patients.
Used with PET imaging, the compound targets vesicular monoamine transporters (VMAT2) in the brain and may enable more accurate and earlier diagnosis of neurodegenerative diseases, according to Avid.
Avid has an exclusive licensing agreement with the University of Michigan and University of Pennsylvania for use of its compounds in VMAT2 imaging.